SWOG 1201: A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Crossed-Complementing 1) for Advanced/Metastatic Esophageal, Gastric, or Gastroesophageal Junction (GEJ) Cancer

CTO - 7548
Cancer - Gastro/ Esophageal
Principal Investigator: Robert A Chapman, MD

This randomized phase II trial studies how well oxaliplatin, leucovorin calcium, and fluorouracil work compared to irinotecan hydrochloride and docetaxel in treating patients with esophageal cancer, gastric cancer, or gastroesophageal junction cancer.

  1. Males and females at least 18 years of age
  2. Confirmed esophageal, stomach, or GEJ cancer; HER-2 negative with available tumor
Open
Tiffany Pearce
(313) 916-1784